|
US976534A
(en)
|
1909-09-15 |
1910-11-22 |
August Wolff |
Window.
|
|
US3687808A
(en)
|
1969-08-14 |
1972-08-29 |
Univ Leland Stanford Junior |
Synthetic polynucleotides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5367066A
(en)
|
1984-10-16 |
1994-11-22 |
Chiron Corporation |
Oligonucleotides with selectably cleavable and/or abasic sites
|
|
FR2575751B1
(fr)
|
1985-01-08 |
1987-04-03 |
Pasteur Institut |
Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
|
|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
FR2594438B1
(fr)
|
1986-02-14 |
1990-01-26 |
Labaz Sanofi Nv |
Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
|
|
US5322691A
(en)
|
1986-10-02 |
1994-06-21 |
Sohrab Darougar |
Ocular insert with anchoring protrusions
|
|
US5116742A
(en)
|
1986-12-03 |
1992-05-26 |
University Patents, Inc. |
RNA ribozyme restriction endoribonucleases and methods
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
EP0366685B1
(en)
|
1987-06-24 |
1994-10-19 |
Howard Florey Institute Of Experimental Physiology And Medicine |
Nucleoside derivatives
|
|
IL87181A
(en)
|
1987-08-07 |
1993-08-18 |
Sanofi Sa |
Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them
|
|
US4914210A
(en)
|
1987-10-02 |
1990-04-03 |
Cetus Corporation |
Oligonucleotide functionalizing reagents
|
|
US5175273A
(en)
|
1988-07-01 |
1992-12-29 |
Genentech, Inc. |
Nucleic acid intercalating agents
|
|
US5468468A
(en)
|
1989-02-09 |
1995-11-21 |
The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services |
Method for making a monoclonal antibody, monoclonal antibodies to α PD
|
|
US5244805A
(en)
|
1989-05-17 |
1993-09-14 |
University Of Georgia Research Foundation, Inc. |
Baculovirus expression vectors
|
|
US5194596A
(en)
*
|
1989-07-27 |
1993-03-16 |
California Biotechnology Inc. |
Production of vascular endothelial cell growth factor
|
|
US5134066A
(en)
|
1989-08-29 |
1992-07-28 |
Monsanto Company |
Improved probes using nucleosides containing 3-dezauracil analogs
|
|
US5225347A
(en)
|
1989-09-25 |
1993-07-06 |
Innovir Laboratories, Inc. |
Therapeutic ribozyme compositions and expression vectors
|
|
US5130302A
(en)
|
1989-12-20 |
1992-07-14 |
Boron Bilogicals, Inc. |
Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
|
|
US5459255A
(en)
|
1990-01-11 |
1995-10-17 |
Isis Pharmaceuticals, Inc. |
N-2 substituted purines
|
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
|
US5681941A
(en)
|
1990-01-11 |
1997-10-28 |
Isis Pharmaceuticals, Inc. |
Substituted purines and oligonucleotide cross-linking
|
|
US6168778B1
(en)
|
1990-06-11 |
2001-01-02 |
Nexstar Pharmaceuticals, Inc. |
Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
|
|
US5674685A
(en)
|
1990-06-11 |
1997-10-07 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
|
US5707796A
(en)
|
1990-06-11 |
1998-01-13 |
Nexstar Pharmaceuticals, Inc. |
Method for selecting nucleic acids on the basis of structure
|
|
US5270163A
(en)
|
1990-06-11 |
1993-12-14 |
University Research Corporation |
Methods for identifying nucleic acid ligands
|
|
US5637459A
(en)
|
1990-06-11 |
1997-06-10 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: chimeric selex
|
|
US5668264A
(en)
|
1990-06-11 |
1997-09-16 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
|
US5763177A
(en)
|
1990-06-11 |
1998-06-09 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
|
|
US5660985A
(en)
|
1990-06-11 |
1997-08-26 |
Nexstar Pharmaceuticals, Inc. |
High affinity nucleic acid ligands containing modified nucleotides
|
|
US5580737A
(en)
|
1990-06-11 |
1996-12-03 |
Nexstar Pharmaceuticals, Inc. |
High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
|
|
US6395888B1
(en)
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
|
US5811533A
(en)
|
1990-06-11 |
1998-09-22 |
Nexstar Pharmaceuticals, Inc. |
High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
|
|
US6011020A
(en)
|
1990-06-11 |
2000-01-04 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
|
CA2084987C
(en)
|
1990-06-11 |
2007-02-13 |
Gilead Sciences, Inc. |
Nucleic acid ligands
|
|
US5459015A
(en)
|
1990-06-11 |
1995-10-17 |
Nexstar Pharmaceuticals, Inc. |
High-affinity RNA ligands of basic fibroblast growth factor
|
|
US5496938A
(en)
|
1990-06-11 |
1996-03-05 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligands to HIV-RT and HIV-1 rev
|
|
US5567588A
(en)
|
1990-06-11 |
1996-10-22 |
University Research Corporation |
Systematic evolution of ligands by exponential enrichment: Solution SELEX
|
|
US5683867A
(en)
|
1990-06-11 |
1997-11-04 |
Nexstar Pharmaceuticals, Inc. |
Systematic evolution of ligands by exponential enrichment: blended SELEX
|
|
US6465188B1
(en)
|
1990-06-11 |
2002-10-15 |
Gilead Sciences, Inc. |
Nucleic acid ligand complexes
|
|
US6147204A
(en)
|
1990-06-11 |
2000-11-14 |
Nexstar Pharmaceuticals, Inc. |
Nucleic acid ligand complexes
|
|
EP0544824B1
(en)
|
1990-07-27 |
1997-06-11 |
Isis Pharmaceuticals, Inc. |
Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
|
|
US5432272A
(en)
|
1990-10-09 |
1995-07-11 |
Benner; Steven A. |
Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
|
|
JPH06503966A
(ja)
|
1990-12-21 |
1994-05-12 |
クリエイティブ バイオモレキュルズ インコーポレイテッド |
生合成したｐｄｇｆアンタゴニスト
|
|
DK0584082T3
(da)
|
1991-01-31 |
2000-10-16 |
Univ California |
Domæner i den ekstracellulære region af humane blodpladeafledte vækstfaktorreceptorpolypeptider
|
|
GB9106678D0
(en)
|
1991-03-28 |
1991-05-15 |
Ferguson Mark W J |
Wound healing
|
|
AU658646B2
(en)
|
1991-05-10 |
1995-04-27 |
Rhone-Poulenc Rorer International (Holdings) Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
US5480883A
(en)
|
1991-05-10 |
1996-01-02 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
US6762290B1
(en)
|
1999-07-29 |
2004-07-13 |
Gilead Sciences, Inc. |
High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
ATE181571T1
(de)
|
1991-09-23 |
1999-07-15 |
Medical Res Council |
Methoden zur herstellung humanisierter antikörper
|
|
US5594121A
(en)
|
1991-11-07 |
1997-01-14 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified purines
|
|
TW393513B
(en)
|
1991-11-26 |
2000-06-11 |
Isis Pharmaceuticals Inc |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5484908A
(en)
|
1991-11-26 |
1996-01-16 |
Gilead Sciences, Inc. |
Oligonucleotides containing 5-propynyl pyrimidines
|
|
AU3222793A
(en)
|
1991-11-26 |
1993-06-28 |
Gilead Sciences, Inc. |
Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
|
|
US5817310A
(en)
|
1991-12-02 |
1998-10-06 |
Cor Therapeutics, Inc. |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
|
|
US5238950A
(en)
|
1991-12-17 |
1993-08-24 |
Schering Corporation |
Inhibitors of platelet-derived growth factor
|
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
TW225528B
(enExample)
|
1992-04-03 |
1994-06-21 |
Ciba Geigy Ag |
|
|
US5756291A
(en)
|
1992-08-21 |
1998-05-26 |
Gilead Sciences, Inc. |
Aptamers specific for biomolecules and methods of making
|
|
US5821234A
(en)
|
1992-09-10 |
1998-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
|
US5869462A
(en)
|
1992-09-10 |
1999-02-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibition of proliferation of vascular smooth muscle cell
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
US5976534A
(en)
|
1993-02-25 |
1999-11-02 |
Zymogenetics, Inc. |
Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
|
|
US5620687A
(en)
|
1993-02-25 |
1997-04-15 |
Zymogenetics, Inc. |
Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
|
|
US5641756A
(en)
|
1993-07-27 |
1997-06-24 |
Hybridon, Inc. |
Modified VEGF oligonucleotides
|
|
US5731294A
(en)
|
1993-07-27 |
1998-03-24 |
Hybridon, Inc. |
Inhibition of neovasularization using VEGF-specific oligonucleotides
|
|
US6410322B1
(en)
|
1993-07-27 |
2002-06-25 |
Hybridon Inc |
Antisense oligonucleotide inhibition of vascular endothelial growth factor expression
|
|
US5502177A
(en)
|
1993-09-17 |
1996-03-26 |
Gilead Sciences, Inc. |
Pyrimidine derivatives for labeled binding partners
|
|
US5952304A
(en)
|
1993-10-22 |
1999-09-14 |
Trigen Limited |
Platelet-derived growth factor analogues
|
|
US5919455A
(en)
|
1993-10-27 |
1999-07-06 |
Enzon, Inc. |
Non-antigenic branched polymer conjugates
|
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
US5457187A
(en)
|
1993-12-08 |
1995-10-10 |
Board Of Regents University Of Nebraska |
Oligonucleotides containing 5-fluorouracil
|
|
AU5698094A
(en)
*
|
1993-12-09 |
1995-06-27 |
Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh |
Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US5861499A
(en)
|
1994-02-10 |
1999-01-19 |
Imclone Systems Incorporated |
Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
|
|
US6448077B1
(en)
|
1994-02-10 |
2002-09-10 |
Imclone Systems, Inc. |
Chimeric and humanized monoclonal antibodies specific to VEGF receptors
|
|
US5840301A
(en)
|
1994-02-10 |
1998-11-24 |
Imclone Systems Incorporated |
Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
|
|
US5596091A
(en)
|
1994-03-18 |
1997-01-21 |
The Regents Of The University Of California |
Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
|
|
US5525711A
(en)
|
1994-05-18 |
1996-06-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pteridine nucleotide analogs as fluorescent DNA probes
|
|
US5958942A
(en)
|
1994-07-15 |
1999-09-28 |
Takeda Chemical Industries, Ltd. |
Tricyclic nitrogen ring compounds, their production and use
|
|
CA2156767A1
(en)
|
1994-08-25 |
1996-02-26 |
Kenichi Matsunaga |
Binding agent for growth factor
|
|
US5476851A
(en)
|
1994-09-08 |
1995-12-19 |
Rhone-Poulenc Rorer Pharmaceuticals, Inc. |
Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
|
|
US5795910A
(en)
|
1994-10-28 |
1998-08-18 |
Cor Therapeutics, Inc. |
Method and compositions for inhibiting protein kinases
|
|
US6403088B1
(en)
|
1995-08-01 |
2002-06-11 |
Helsinki University Licensing, Ltd. |
Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
|
|
US5932462A
(en)
|
1995-01-10 |
1999-08-03 |
Shearwater Polymers, Inc. |
Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
|
|
US5723750A
(en)
|
1995-01-12 |
1998-03-03 |
Vanderbilt University |
Transgenic plants expressing disassembly deficient viral coat proteins
|
|
US5928939A
(en)
|
1995-03-01 |
1999-07-27 |
Ludwig Institute For Cancer Research |
Vascular endothelial growth factor-b and dna coding therefor
|
|
US5611135A
(en)
|
1995-03-21 |
1997-03-18 |
Dana Corporation |
Method of making a tube yoke for drive line assembly
|
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
|
US5859228A
(en)
|
1995-05-04 |
1999-01-12 |
Nexstar Pharmaceuticals, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
US6331555B1
(en)
|
1995-06-01 |
2001-12-18 |
University Of California |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
US6207816B1
(en)
|
1995-06-02 |
2001-03-27 |
Nexstar Pharmaceuticals, Inc. |
High affinity oligonucleotide ligands to growth factors
|
|
US5723594A
(en)
|
1995-06-07 |
1998-03-03 |
Nexstar Pharmaceuticals, Inc. |
High affinity PDGF nucleic acid ligands
|
|
US6229002B1
(en)
|
1995-06-07 |
2001-05-08 |
Nexstar Pharmaceuticlas, Inc. |
Platelet derived growth factor (PDGF) nucleic acid ligand complexes
|
|
US5618837A
(en)
|
1995-06-07 |
1997-04-08 |
Zymogenetics, Inc. |
PDGF antagonists III
|
|
US6699843B2
(en)
*
|
1995-06-07 |
2004-03-02 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to PDGF
|
|
ES2217313T3
(es)
|
1995-06-30 |
2004-11-01 |
Zymogenetics, Inc. |
Bencenosulfonamidas o sulfonilureas de 4-(2-(n-(-2-carboxamidoindol)aminoetilo) como antagonistas del pdfg.
|
|
US6361946B1
(en)
|
1997-02-05 |
2002-03-26 |
Licentia Ltd |
Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
|
|
US5730977A
(en)
|
1995-08-21 |
1998-03-24 |
Mitsui Toatsu Chemicals, Inc. |
Anti-VEGF human monoclonal antibody
|
|
ATE242809T1
(de)
|
1995-09-08 |
2003-06-15 |
Genentech Inc |
Vegf-verwandtes protein
|
|
AU1686997A
(en)
|
1995-12-08 |
1997-06-27 |
Hybridon, Inc. |
Modified vegf antisense oligonucleotides for treatment of skin disorders
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
ATE211134T1
(de)
|
1996-03-05 |
2002-01-15 |
|
4-anilinochinazolin derivate
|
|
WO1997034876A1
(en)
|
1996-03-15 |
1997-09-25 |
Zeneca Limited |
Cinnoline derivatives and use as medicine
|
|
US5882644A
(en)
|
1996-03-22 |
1999-03-16 |
Protein Design Labs, Inc. |
Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
|
|
AU736333B2
(en)
|
1996-05-01 |
2001-07-26 |
Eli Lilly And Company |
Therapeutic treatment for VEGF related diseases
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
FR2752734B1
(fr)
|
1996-09-02 |
1998-11-06 |
Cird Galderma |
Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
|
|
AU738806B2
(en)
|
1996-09-24 |
2001-09-27 |
Merck & Co., Inc. |
Gene therapy for inhibition of angiogenesis
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
AU719392B2
(en)
|
1996-10-01 |
2000-05-11 |
Kyowa Hakko Kirin Co., Ltd. |
Nitrogen-containing heterocyclic compounds
|
|
US6051698A
(en)
*
|
1997-06-06 |
2000-04-18 |
Janjic; Nebojsa |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
US6426335B1
(en)
|
1997-10-17 |
2002-07-30 |
Gilead Sciences, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
|
JP3837748B2
(ja)
|
1997-01-17 |
2006-10-25 |
東亞合成株式会社 |
Ｖｅｇｆ結合性ポリペプチド
|
|
US6291667B1
(en)
|
1997-01-31 |
2001-09-18 |
Parkash S. Gill |
Method and composition for treatment of kaposi's sarcoma
|
|
US20020032315A1
(en)
*
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
US6884879B1
(en)
*
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
KR100870353B1
(ko)
|
1997-04-07 |
2008-11-25 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체
|
|
US6159978A
(en)
|
1997-05-28 |
2000-12-12 |
Aventis Pharmaceuticals Product, Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
US6278039B1
(en)
|
1997-05-28 |
2001-08-21 |
Axys Pharmaceuticals, Inc. |
C. elegans deletion mutants
|
|
US6180632B1
(en)
|
1997-05-28 |
2001-01-30 |
Aventis Pharmaceuticals Products Inc. |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
US6245760B1
(en)
|
1997-05-28 |
2001-06-12 |
Aventis Pharmaceuticals Products, Inc |
Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
|
|
US5932580A
(en)
|
1997-12-01 |
1999-08-03 |
Yissum Research And Development Company Of The Hebrew University Of Jerusalem |
PDGF receptor kinase inhibitory compounds their preparation and compositions
|
|
US6251588B1
(en)
|
1998-02-10 |
2001-06-26 |
Agilent Technologies, Inc. |
Method for evaluating oligonucleotide probe sequences
|
|
WO2000023565A2
(en)
|
1998-10-19 |
2000-04-27 |
Ludwig Institute For Cancer Research |
Novel neuropilin/growth factor binding and uses thereof
|
|
DE69931178T8
(de)
|
1998-11-02 |
2007-06-28 |
Ludwig Institute For Cancer Research |
Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
|
|
GB9824579D0
(en)
|
1998-11-10 |
1999-01-06 |
Novartis Ag |
Organic compounds
|
|
EP1135498B1
(en)
|
1998-11-18 |
2008-01-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
|
DK1140175T3
(da)
|
1998-12-21 |
2006-08-14 |
Ludwig Inst Cancer Res |
Antistoffer mod trunkeret VEGF-D og anvendelser deraf
|
|
US6110462A
(en)
|
1999-03-03 |
2000-08-29 |
The Scripps Research Institute |
Enzymatic DNA molecules that contain modified nucleotides
|
|
WO2000060115A2
(en)
|
1999-04-02 |
2000-10-12 |
City Of Hope |
Method for identifying accessible binding sites on rna
|
|
ES2223705T3
(es)
|
1999-04-28 |
2005-03-01 |
Board Of Regents, The University Of Texas System |
Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
|
|
US7306799B2
(en)
|
1999-06-08 |
2007-12-11 |
Regeneron Pharmaceuticals, Inc. |
Use of VEGF inhibitors for treatment of eye disorders
|
|
US6382219B1
(en)
*
|
1999-06-08 |
2002-05-07 |
Jeffery A. Jelten |
Tooth flossing device
|
|
US7070959B1
(en)
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
|
US7303746B2
(en)
*
|
1999-06-08 |
2007-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with modified chimeric polypeptides
|
|
US7078390B1
(en)
*
|
1999-10-15 |
2006-07-18 |
Gentier Biosystems Incorporation |
Ribozymes to growth factor originating in human platelet
|
|
DE60040876D1
(de)
|
1999-10-21 |
2009-01-02 |
Alcon Inc |
Medikamentenzuführeinrichtung
|
|
US6358954B1
(en)
|
1999-11-09 |
2002-03-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
|
|
TWI310684B
(en)
*
|
2000-03-27 |
2009-06-11 |
Bristol Myers Squibb Co |
Synergistic pharmaceutical kits for treating cancer
|
|
JP2003528632A
(ja)
|
2000-03-31 |
2003-09-30 |
インスティティ・パスツール |
血管内皮成長因子（ｖｅｇｆ）−媒介性脈管形成を阻害するペプチド、該ペプチドをエンコードするポリヌクレオチド及びその使用方法
|
|
WO2001087351A1
(en)
|
2000-05-17 |
2001-11-22 |
Gilead Sciences, Inc. |
Method for treatment of tumors using nucleic acid ligands to pdgf
|
|
ATE404140T1
(de)
|
2000-08-30 |
2008-08-15 |
Univ Johns Hopkins |
Vorrichtung zur intraokularen wirkstoffverabreichung
|
|
WO2003070910A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
GB0119249D0
(en)
|
2001-08-07 |
2001-10-03 |
Novartis Ag |
Organic compounds
|
|
FR2828601B1
(fr)
|
2001-08-10 |
2003-11-07 |
Iroc Technologies |
Ensemble de circuits electroniques comportant des moyens de decontamination de parties contaminees par des erreurs
|
|
US6927293B2
(en)
*
|
2001-08-30 |
2005-08-09 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
EP1436329A4
(en)
|
2001-09-20 |
2005-04-27 |
Alexion Pharma Inc |
ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES
|
|
HRP20040406A2
(en)
|
2001-11-09 |
2005-02-28 |
Eyetech Pharmaceuticals |
Methods for treating ocular neovascular diseases
|
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
|
AR037647A1
(es)
|
2002-05-29 |
2004-12-01 |
Novartis Ag |
Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
|
|
CA2487809A1
(en)
*
|
2002-06-18 |
2003-12-24 |
Archemix Corp. |
Aptamer-toxin molecules and methods for using same
|
|
US20040249130A1
(en)
*
|
2002-06-18 |
2004-12-09 |
Martin Stanton |
Aptamer-toxin molecules and methods for using same
|
|
AU2002368062A1
(en)
|
2002-06-26 |
2004-01-19 |
Imclone Systems Incorporated |
Bispecific antibodies that bind to vegf receptors
|
|
GB0215844D0
(en)
|
2002-07-09 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
US20070184089A1
(en)
|
2002-07-15 |
2007-08-09 |
Alcon, Inc. |
Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
|
|
TWI283406B
(en)
*
|
2002-08-28 |
2007-07-01 |
Brilliance Semiconductor Inc |
Charging-free ultra-low power virtual dynamic random access memory
|
|
JP4412461B2
(ja)
|
2002-11-20 |
2010-02-10 |
日油株式会社 |
修飾された生体関連物質、その製造方法および中間体
|
|
US8003117B2
(en)
|
2002-11-20 |
2011-08-23 |
Nof Corporation |
Polyalkylene glycol derivative and modified bio-related substance
|
|
US8828373B2
(en)
|
2002-11-20 |
2014-09-09 |
Nof Corporation |
Polyalkylene glycol derivative and modified bio-related substance
|
|
AU2003294437A1
(en)
*
|
2002-11-21 |
2004-06-18 |
Archemix Corporation |
Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
|
|
US10100316B2
(en)
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
|
US8039443B2
(en)
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US20040253243A1
(en)
|
2003-01-21 |
2004-12-16 |
David Epstein |
Aptamer therapeutics useful in ocular pharmacotherapy
|
|
US20090053138A1
(en)
*
|
2002-11-21 |
2009-02-26 |
Preiss Jeffrey R |
Stabilized Aptamers to Platelet Derived Growth Factor and their Use as Oncology Therapeutics
|
|
US20050124565A1
(en)
*
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
|
US7459436B2
(en)
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
|
US20050048099A1
(en)
|
2003-01-09 |
2005-03-03 |
Allergan, Inc. |
Ocular implant made by a double extrusion process
|
|
EP1639001A1
(en)
*
|
2003-06-27 |
2006-03-29 |
Dnavec Research Inc. |
Method for transplanting lymphohematopoietic cells into mammal
|
|
AU2004268614C1
(en)
|
2003-08-27 |
2010-10-28 |
Ophthotech Corporation |
Combination therapy for the treatment of ocular neovascular disorders
|
|
US20050063257A1
(en)
*
|
2003-09-24 |
2005-03-24 |
Clark David G. |
Audio bookmark
|
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
|
US8529927B2
(en)
|
2004-04-30 |
2013-09-10 |
Allergan, Inc. |
Alpha-2 agonist polymeric drug delivery systems
|
|
US20050244500A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Intravitreal implants in conjuction with photodynamic therapy to improve vision
|
|
US20050244471A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
|
|
US20050244462A1
(en)
|
2004-04-30 |
2005-11-03 |
Allergan, Inc. |
Devices and methods for treating a mammalian eye
|
|
EP1877438A2
(en)
|
2005-02-02 |
2008-01-16 |
Regeneron Pharmaceuticals, Inc. |
Method of treating eye injury with local administration of a vegf inhibitor
|
|
EP1853298A2
(en)
|
2005-02-11 |
2007-11-14 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
|
|
US20090075342A1
(en)
|
2005-04-26 |
2009-03-19 |
Sharon Cload |
Metabolic profile directed aptamer medicinal chemistry
|
|
US20080152654A1
(en)
|
2006-06-12 |
2008-06-26 |
Exegenics, Inc., D/B/A Opko Health, Inc. |
COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS
|
|
EP3753548A1
(en)
|
2006-06-16 |
2020-12-23 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
EP2091481A2
(en)
|
2006-12-18 |
2009-08-26 |
Alcon Research, Ltd. |
Devices and methods for ophthalmic drug delivery
|
|
EP2166844A4
(en)
*
|
2007-06-07 |
2013-09-04 |
Evonik Corp |
DOSAGE FORMS WITH EXTENDED ACTION AND REDUCED MASS
|
|
EP3028707A1
(en)
|
2009-05-01 |
2016-06-08 |
Ophthotech Corporation |
Methods for treating or preventing ophthalmological diseases
|
|
CN102122763A
(zh)
*
|
2011-03-17 |
2011-07-13 |
东南大学 |
并联馈电的全向阵列天线
|